HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

INNOGEN-B

27.660

+0.0600.22%

Volume:19.60K

Turnover:537.29K

Market Cap:12.64B

PE:-66.45

High:27.700

Open:27.400

Low:27.040

Close:27.600

52wk High:74.000

52wk Low:25.500

Shares:457.00M

HK Float Shares:420.29M

Volume Ratio:0.14

T/O Rate:0.00%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-0.416

ROE:-23.27%

ROA:-11.61%

PB:16.32

PE(LYR):-66.45

PS:197.40

Loading ...

Overview Company News Filings

Guangzhou Innogen (2591) Announces Joint Company Secretary Changes and Waiver Approval

Bulletin Express

INNOGEN-B (02591) Appoints Yang Dongyan as Joint Company Secretary

Guangzhou Innogen Pharmaceutical Appoints Yang as Joint Company Secretary

BUZZ-Guangzhou Innogen jumps most in 10 weeks on Veterinary Drug Application

Guangzhou Innogen Pharmaceutical (2591) Announces Acceptance of Investigational New Veterinary Drug Application for Efsubaglutide Alfa

Bulletin Express

INNOGEN-B (02591) Announces Acceptance of New Veterinary Drug Clinical Trial Application for Esupaglutide α

BRIEF-Guangzhou Innogen Pharmaceutical Says Veterinary Drug Application Accepted By MARA

Guangzhou Innogen Pharmaceutical Gets Investigational New Veterinary Drug Application for Efsubaglutide Alfa Accepted in China

Guangzhou Innogen Pharmaceutical Group Co Ltd - Investigational New Veterinary Drug Application Accepted by Mara

THOMSON REUTERS

Guangzhou Innogen (02591) Announces Monthly Return for January 2026

Bulletin Express

From Sharp Post-Connect Decline to "Doji Star": Is INNOGEN-B (02591) Nearing a Turning Point After Low-Level Consolidation?

HK Stock Movement | INNOGEN-B (02591) Rises Over 3% Intraday as Esupaglutide α Recommended in National Diabetes Prevention Guidelines

HKEX Announcement Highlights | Guoxia Tech Plans Global Offering of 33.85M H Shares, Secures Cornerstone Investors Including Wui Kai Hong

Innogen Pharma Added to Stock Connect Programs

MT Newswires Live

INNOGEN-B (02591) Pulls Back Over 13% After 50% Rally in Two Weeks, Officially Added to Stock Connect Today

INNOGEN-B (02591) Core Product Included in China's National Reimbursement Drug List

Guangzhou Innogen's Efsubaglutide Alfa Added to China's National Reimbursement Drug List

INNOGEN-B (02591) Rises Over 5% Again, Set to Join Hang Seng Composite Index Next Monday; Analysts Say It Meets Southbound Trading Eligibility

Guangzhou Innogen (02591) Announces Monthly Share Capital Update

Bulletin Express

Innogen Pharma and Unit Invest 125 Million Yuan in Bank of Ningbo Structured Products; Shares Slip 2%

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/02591/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02591","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02591\",,,,,undefined,":{"symbol":"02591","market":"HK","secType":"STK","nameCN":"INNOGEN-B","latestPrice":27.66,"timestamp":1771214700046,"preClose":27.6,"halted":0,"volume":19600,"delay":0,"changeRate":0.0021739130434782145,"floatShares":420285370,"shares":457000000,"eps":-0.416279,"marketStatus":"Closed The third day of Lunar New Year","change":0.06,"latestTime":"02-16 12:05:00","open":27.4,"high":27.7,"low":27.04,"amount":537288,"amplitude":0.023913,"askPrice":27.7,"askSize":16600,"bidPrice":27.24,"bidSize":800,"shortable":0,"etf":0,"ttmEps":-0.533,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1771551000000},"marketStatusCode":7,"adr":0,"listingDate":1755187200000,"exchange":"SEHK","adjPreClose":27.6,"openAndCloseTimeList":[[1771205400000,1771214400000]],"volumeRatio":0.13787810956773097,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02591\",,,,,undefined,":{"symbol":"02591","floatShares":420285370,"roa":"-11.61%","roe":"-23.27%","lyrEps":-0.416279,"volumeRatio":0.13787810956773097,"shares":457000000,"dividePrice":0,"high":27.7,"amplitude":0.023913,"preClose":27.6,"low":27.04,"week52Low":25.5,"pbRate":"16.32","psRate":"197.40","week52High":74,"institutionHeld":0,"latestPrice":27.66,"committee":-0.908046,"eps":-0.416279,"divideRate":0,"volume":19600,"delay":0,"ttmEps":-0.533,"open":27.4,"prevYearClose":30.64,"prevWeekClose":27.6,"prevMonthClose":29.8,"prevQuarterClose":30.64,"fiveDayClose":27.24,"twentyDayClose":30.86,"sixtyDayClose":31.82},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02591\",params:#limit:5,,,undefined,":[{"date":"2025-08-29","symbol":"02591","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756431000000,"name":null,"time":"","dateTimestamp":1756396800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02591\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02591\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02591\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02591","date":"2026-02-16","current":-51.894934,"percent":0.944,"low":-137.156472,"twenty":-79.659463,"median":-62.792795,"eighty":-56.980838,"high":-47.228587,"avg":-70.43717,"sd":19.6454,"marketCap":12635623193},"quantilePoints":[{"date":"2025-08-15","current":-137.156472,"twenty":-137.156472,"median":-137.156472,"eighty":-137.156472,"marketCap":26152907730},{"date":"2025-08-22","current":-127.373977,"twenty":-129.344203,"median":-127.373977,"eighty":-126.417438,"marketCap":24211425497},{"date":"2025-08-29","current":-106.390102,"twenty":-127.373977,"median":-126.095992,"eighty":-114.007182,"marketCap":20319324643},{"date":"2025-09-05","current":-78.151342,"twenty":-127.373977,"median":-117.586994,"eighty":-99.491273,"marketCap":18939730209},{"date":"2025-09-12","current":-83.843855,"twenty":-126.417438,"median":-105.433356,"eighty":-83.374192,"marketCap":20355870191},{"date":"2025-09-19","current":-79.271387,"twenty":-126.095992,"median":-93.890147,"eighty":-81.90749,"marketCap":19232094592},{"date":"2025-09-26","current":-78.986763,"twenty":-125.916102,"median":-85.498552,"eighty":-79.429082,"marketCap":19113321562},{"date":"2025-10-03","current":-76.5387,"twenty":-122.116665,"median":-83.843855,"eighty":-78.76383,"marketCap":18565138343},{"date":"2025-10-10","current":-69.068341,"twenty":-116.871032,"median":-83.374192,"eighty":-77.810518,"marketCap":16728724560},{"date":"2025-10-17","current":-67.838616,"twenty":-109.436934,"median":-79.738352,"eighty":-74.826182,"marketCap":16418087403},{"date":"2025-10-24","current":-59.813644,"twenty":-105.816054,"median":-79.429082,"eighty":-68.576451,"marketCap":14481173363},{"date":"2025-10-31","current":-57.61442,"twenty":-103.460611,"median":-78.986763,"eighty":-66.346017,"marketCap":13969535692},{"date":"2025-11-07","current":-56.556997,"twenty":-100.097405,"median":-78.243448,"eighty":-63.14919,"marketCap":13704580470},{"date":"2025-11-14","current":-61.96171,"twenty":-95.010372,"median":-77.299283,"eighty":-61.326336,"marketCap":15056765743},{"date":"2025-11-21","current":-54.467459,"twenty":-87.179427,"median":-75.823033,"eighty":-60.1184,"marketCap":13229488347},{"date":"2025-11-28","current":-82.342484,"twenty":-85.508442,"median":-76.5387,"eighty":-60.703449,"marketCap":20072642195},{"date":"2025-12-05","current":-82.313405,"twenty":-85.248884,"median":-75.823033,"eighty":-61.326336,"marketCap":20100051356},{"date":"2025-12-12","current":-63.824496,"twenty":-84.462171,"median":-74.404407,"eighty":-61.326336,"marketCap":15614085348},{"date":"2025-12-19","current":-62.072323,"twenty":-83.725798,"median":-74.049705,"eighty":-60.286674,"marketCap":15221220708},{"date":"2025-12-24","current":-59.762449,"twenty":-83.548712,"median":-73.276127,"eighty":-59.816947,"marketCap":14700446650},{"date":"2026-01-02","current":-56.27243,"twenty":-83.409096,"median":-71.366231,"eighty":-59.572219,"marketCap":13896444596},{"date":"2026-01-09","current":-57.1291,"twenty":-82.548826,"median":-69.803372,"eighty":-58.239982,"marketCap":14143127045},{"date":"2026-01-16","current":-56.980838,"twenty":-82.319221,"median":-67.499105,"eighty":-57.682607,"marketCap":14152263432},{"date":"2026-01-23","current":-58.213825,"twenty":-82.096799,"median":-66.291021,"eighty":-57.601428,"marketCap":14444627815},{"date":"2026-01-30","current":-54.613459,"twenty":-81.934522,"median":-64.906051,"eighty":-57.510573,"marketCap":13613216600},{"date":"2026-02-06","current":-49.064319,"twenty":-80.235292,"median":-63.834,"eighty":-57.242442,"marketCap":12261031327},{"date":"2026-02-13","current":-50.165477,"twenty":-79.691019,"median":-62.941647,"eighty":-57.039695,"marketCap":12608214032},{"date":"2026-02-16","current":-50.333041,"twenty":-79.659463,"median":-62.792795,"eighty":-56.980838,"marketCap":12635623193}],"updateTime":1771410250978},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02591\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1193841516","title":"Guangzhou Innogen (2591) Announces Joint Company Secretary Changes and Waiver Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=1193841516","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1193841516?lang=en_us&edition=fundamental","pubTime":"2026-02-06 17:02","pubTimestamp":1770368521,"startTime":"0","endTime":"0","summary":"Guangzhou Innogen Pharmaceutical Group Co., Ltd. (Stock Code: 2591) announced that a joint company secretary, Ms. Jin Jin, resigned effective 6 February 2026 for personal development reasons. Ms. Jin...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591"],"gpt_icon":0},{"id":"1160518198","title":"INNOGEN-B (02591) Appoints Yang Dongyan as Joint Company Secretary","url":"https://stock-news.laohu8.com/highlight/detail?id=1160518198","media":"Stock News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1160518198?lang=en_us&edition=fundamental","pubTime":"2026-02-06 16:46","pubTimestamp":1770367584,"startTime":"0","endTime":"0","summary":"INNOGEN-B (02591) announced that Ms. Jin Jin has resigned as joint company secretary for personal development reasons, effective February 6, 2026. Ms. Yang Dongyan has been appointed as joint company...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591","BK1161"],"gpt_icon":0},{"id":"2609563466","title":"Guangzhou Innogen Pharmaceutical Appoints Yang as Joint Company Secretary","url":"https://stock-news.laohu8.com/highlight/detail?id=2609563466","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609563466?lang=en_us&edition=fundamental","pubTime":"2026-02-06 16:40","pubTimestamp":1770367227,"startTime":"0","endTime":"0","summary":"Guangzhou Innogen Pharmaceutical Group Co. Ltd. has announced that Ms. Jin Jin has resigned as joint company secretary, effective 6 February 2026, and Ms. Yang has been appointed as the new joint company secretary.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guangzhou Innogen Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on February 06, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260206:nNDL2JrjYP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591","BK1161"],"gpt_icon":0},{"id":"2609349781","title":"BUZZ-Guangzhou Innogen jumps most in 10 weeks on Veterinary Drug Application","url":"https://stock-news.laohu8.com/highlight/detail?id=2609349781","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609349781?lang=en_us&edition=fundamental","pubTime":"2026-02-05 11:35","pubTimestamp":1770262519,"startTime":"0","endTime":"0","summary":"BUZZ-Guangzhou Innogen jumps most in 10 weeks on Veterinary Drug Application** Shares of Guangzhou Innogen Pharmaceutical Group 2591.HK jump 20.1% to HK$31, on track for the biggest one-day pct rise since November 24** Stock hits its highest level since January 30, on course to snap four consecutive sessions of decline; second-biggest pct gainer in the Hang Seng Composite Index on healthcare .HSCIH, which slips 1% ** China-based pharmaceutical products developer says Investigational New Veterinary Drug application for core product Efsubaglutide Alfa for treatment of companion animal diabetes has been accepted by China's Ministry of Agriculture and Rural Affairs ** Says Phase I clinical trials are expected to commence in the first quarter of 2026** YTD, stock down 4.8%, benchmark Hang Seng Index .HSI up 3.4%","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260205:nL1N3Z104W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591","BK1161"],"gpt_icon":0},{"id":"1143745026","title":"Guangzhou Innogen Pharmaceutical (2591) Announces Acceptance of Investigational New Veterinary Drug Application for Efsubaglutide Alfa","url":"https://stock-news.laohu8.com/highlight/detail?id=1143745026","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1143745026?lang=en_us&edition=fundamental","pubTime":"2026-02-04 23:04","pubTimestamp":1770217456,"startTime":"0","endTime":"0","summary":"Guangzhou Innogen Pharmaceutical Group Co., Ltd. (Stock Code: 2591) disclosed that on 4 February 2026, the Ministry of Agriculture and Rural Affairs of the People’s Republic of China accepted its...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591"],"gpt_icon":0},{"id":"1132560248","title":"INNOGEN-B (02591) Announces Acceptance of New Veterinary Drug Clinical Trial Application for Esupaglutide α","url":"https://stock-news.laohu8.com/highlight/detail?id=1132560248","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1132560248?lang=en_us&edition=fundamental","pubTime":"2026-02-04 22:25","pubTimestamp":1770215109,"startTime":"0","endTime":"0","summary":"INNOGEN-B (02591) has issued an announcement disclosing that on February 4, 2026, the application for a new veterinary drug clinical trial for the company's core product, Esupaglutide α, intended for...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591","BK1161"],"gpt_icon":0},{"id":"2608360965","title":"BRIEF-Guangzhou Innogen Pharmaceutical Says Veterinary Drug Application Accepted By MARA","url":"https://stock-news.laohu8.com/highlight/detail?id=2608360965","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608360965?lang=en_us&edition=fundamental","pubTime":"2026-02-04 22:19","pubTimestamp":1770214764,"startTime":"0","endTime":"0","summary":"BRIEF-Guangzhou Innogen Pharmaceutical Says Veterinary Drug Application Accepted By MARAFeb 4 (Reuters) - Guangzhou Innogen Pharmaceutical Group Co Ltd 2591.HK:INVESTIGATIONAL NEW VETERINARY DRUG APPLICATION ACCEPTED BY MARAFurther company coverage: 2591.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260204:nFWN3Z00NT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02591"],"gpt_icon":0},{"id":"2608236060","title":"Guangzhou Innogen Pharmaceutical Gets Investigational New Veterinary Drug Application for Efsubaglutide Alfa Accepted in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2608236060","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608236060?lang=en_us&edition=fundamental","pubTime":"2026-02-04 22:17","pubTimestamp":1770214664,"startTime":"0","endTime":"0","summary":"Guangzhou Innogen Pharmaceutical Gets Investigational New Veterinary Drug Application for Efsubaglutide Alfa Accepted in China. Guangzhou Innogen Pharmaceutical Group Co., Ltd. announced that the Ministry of Agriculture and Rural Affairs of the People's Republic of China has officially accepted its Investigational New Veterinary Drug application for Efsubaglutide Alfa, a core product intended for the treatment of companion animal diabetes. The company expects to commence Phase I clinical trials in the first quarter of 2026. The company indicated that this acceptance provides a basis for future clinical trials and registration applications related to the drug.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guangzhou Innogen Pharmaceutic","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260204:nNDL3l8DdN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02591"],"gpt_icon":0},{"id":"2608360674","title":"Guangzhou Innogen Pharmaceutical Group Co Ltd - Investigational New Veterinary Drug Application Accepted by Mara","url":"https://stock-news.laohu8.com/highlight/detail?id=2608360674","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608360674?lang=en_us&edition=fundamental","pubTime":"2026-02-04 22:17","pubTimestamp":1770214637,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260204:nFWN3Z00NT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","02591"],"gpt_icon":0},{"id":"1182093044","title":"Guangzhou Innogen (02591) Announces Monthly Return for January 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1182093044","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1182093044?lang=en_us&edition=fundamental","pubTime":"2026-02-03 17:09","pubTimestamp":1770109767,"startTime":"0","endTime":"0","summary":"Guangzhou Innogen Pharmaceutical Group Co., Ltd. (stock code: 02591) released its monthly return for equity securities as of January 31, 2026. According to the announcement, the total authorized...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591"],"gpt_icon":0},{"id":"1187454123","title":"From Sharp Post-Connect Decline to \"Doji Star\": Is INNOGEN-B (02591) Nearing a Turning Point After Low-Level Consolidation?","url":"https://stock-news.laohu8.com/highlight/detail?id=1187454123","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1187454123?lang=en_us&edition=fundamental","pubTime":"2026-01-31 12:39","pubTimestamp":1769834355,"startTime":"0","endTime":"0","summary":"Throughout the eventful year of 2025, the fervent Hong Kong IPO market birthed numerous \"star IPO candidates,\" and among this constellation of stars, INNOGEN-B (02591) still managed to stand out with...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02591"],"gpt_icon":0},{"id":"1125323298","title":"HK Stock Movement | INNOGEN-B (02591) Rises Over 3% Intraday as Esupaglutide α Recommended in National Diabetes Prevention Guidelines","url":"https://stock-news.laohu8.com/highlight/detail?id=1125323298","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1125323298?lang=en_us&edition=fundamental","pubTime":"2025-12-17 11:06","pubTimestamp":1765940775,"startTime":"0","endTime":"0","summary":"INNOGEN-B (02591) surged over 3% intraday, reaching a 3.43% gain at press time to HK$32, with a turnover of HK$20.74 million. The company announced via its official WeChat account that Esupaglutide α...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02591"],"gpt_icon":0},{"id":"1187723737","title":"HKEX Announcement Highlights | Guoxia Tech Plans Global Offering of 33.85M H Shares, Secures Cornerstone Investors Including Wui Kai Hong","url":"https://stock-news.laohu8.com/highlight/detail?id=1187723737","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1187723737?lang=en_us&edition=fundamental","pubTime":"2025-12-08 23:08","pubTimestamp":1765206503,"startTime":"0","endTime":"0","summary":"Key Developments:   - **Guoxia Tech (02655)**: Opens IPO subscription from Dec 8–11, proposing a global offering of 33.85 million H shares with cornerstone investors like Wui Kai Hong.   - **CStone...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1154","HK0000252152.HKD","SG9999006597.SGD","LU0449509016.USD","00956","BK1166","SG9999001069.SGD","BK1119","BK1503","SG9999003461.SGD","00489","BK1594","LU0449515922.USD","BK1148","BK1539","LU0531970944.HKD","01618","LU0823040885.USD","SG9999001051.SGD","02655","LU0214875030.USD","HK0000252160.HKD","BK1565","LU0254981946.USD","SG9999002950.SGD","BK1583","BK1240","SGXZ90724238.SGD","HK0000500386.USD","00916","BK1149","SG9999001093.SGD","02591","BK1558","06166","LU0054450605.USD","BK1523"],"gpt_icon":0},{"id":"2589386476","title":"Innogen Pharma Added to Stock Connect Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2589386476","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589386476?lang=en_us&edition=fundamental","pubTime":"2025-12-08 12:57","pubTimestamp":1765169861,"startTime":"0","endTime":"0","summary":"Guangzhou Innogen Pharmaceutical  said its H shares have been added to both the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect programs, effective Monday, according to a same-day bourse filing.The inclusion will allow mainland investors to trade the company's H shares through the Shanghai and Shenzhen stock exchanges.The board said the move is expected to broaden the firm's investor base, boost liquidity, and strengthen its profile in the capital market.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02591","BK1161"],"gpt_icon":0},{"id":"1123349506","title":"INNOGEN-B (02591) Pulls Back Over 13% After 50% Rally in Two Weeks, Officially Added to Stock Connect Today","url":"https://stock-news.laohu8.com/highlight/detail?id=1123349506","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1123349506?lang=en_us&edition=fundamental","pubTime":"2025-12-08 10:24","pubTimestamp":1765160654,"startTime":"0","endTime":"0","summary":"INNOGEN-B (02591) retreated more than 13%, following a 50% surge over the past two weeks. At the time of writing, the stock fell 13.64% to HK$38, with a turnover of HK$30.31 million. The Shanghai and...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591","BK1161"],"gpt_icon":1},{"id":"1111408676","title":"INNOGEN-B (02591) Core Product Included in China's National Reimbursement Drug List","url":"https://stock-news.laohu8.com/highlight/detail?id=1111408676","media":"Stock News","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111408676?lang=en_us&edition=fundamental","pubTime":"2025-12-07 19:22","pubTimestamp":1765106529,"startTime":"0","endTime":"0","summary":"INNOGEN-B (02591) announced that its core product, Esupaglutide α, has been successfully included in the latest edition of China's National Reimbursement Drug List (2025 version) for the treatment of type 2 diabetes (T2D). The updated list will officially take effect on January 1, 2026.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02591"],"gpt_icon":0},{"id":"2589874104","title":"Guangzhou Innogen's Efsubaglutide Alfa Added to China's National Reimbursement Drug List","url":"https://stock-news.laohu8.com/highlight/detail?id=2589874104","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589874104?lang=en_us&edition=fundamental","pubTime":"2025-12-07 19:16","pubTimestamp":1765106199,"startTime":"0","endTime":"0","summary":"Guangzhou Innogen Pharmaceutical Group Co., Ltd. announced that its core product, Efsubaglutide Alfa, has been included in the latest National Reimbursement Drug List  of China for the treatment of type 2 diabetes. This regulatory approval will take effect from January 1, 2026. Efsubaglutide Alfa is the first domestically developed innovative humanised, long-acting GLP-1 receptor agonist by the company, approved earlier this year in China for use as a monotherapy and in combination with metformin.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guangzhou Innogen Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  ,","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251207:nNDL2hS5T3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02591"],"gpt_icon":0},{"id":"1131099379","title":"INNOGEN-B (02591) Rises Over 5% Again, Set to Join Hang Seng Composite Index Next Monday; Analysts Say It Meets Southbound Trading Eligibility","url":"https://stock-news.laohu8.com/highlight/detail?id=1131099379","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131099379?lang=en_us&edition=fundamental","pubTime":"2025-12-05 10:12","pubTimestamp":1764900730,"startTime":"0","endTime":"0","summary":"INNOGEN-B (02591) surged over 5% again, marking a three-day winning streak. At press time, the stock rose 5.03% to HK$43.42, with a turnover of HK$7.64 million. The Hang Seng Indexes Company...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02591"],"gpt_icon":0},{"id":"1124852786","title":"Guangzhou Innogen (02591) Announces Monthly Share Capital Update","url":"https://stock-news.laohu8.com/highlight/detail?id=1124852786","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1124852786?lang=en_us&edition=fundamental","pubTime":"2025-12-03 17:05","pubTimestamp":1764752713,"startTime":"0","endTime":"0","summary":"Guangzhou Innogen Pharmaceutical Group Co., Ltd. (02591) reported no change in its total authorized share capital for November 2025. The authorized share capital remained at RMB 456,819,349,...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591"],"gpt_icon":0},{"id":"2588086329","title":"Innogen Pharma and Unit Invest 125 Million Yuan in Bank of Ningbo Structured Products; Shares Slip 2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588086329","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588086329?lang=en_us&edition=fundamental","pubTime":"2025-12-02 12:03","pubTimestamp":1764648224,"startTime":"0","endTime":"0","summary":"Guangzhou Innogen Pharmaceutical  and its wholly owned unit Innogen Technology subscribed to a combined 125 million yuan in structured deposit products issued by Bank of Ningbo , according to a Monday Hong Kong bourse filing.Shares of the pharmaceutical firm were down nearly 2% in Tuesday's late morning trade.The parent company subscribed to 75 million yuan, and the subsidiary to 50 million yuan.The subscriptions were funded with internal resources and made after earlier Bank of Ningbo products matured on Nov. 26, the filing said.Innogen said the deposits form part of its treasury management strategy to generate returns on idle cash while maintaining sufficient working capital.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1720050803.USD","SGXZ81163826.USD","LU1794554557.SGD","BK0183","LU2580892862.HKD","LU1655091616.SGD","LU1969619763.USD","BK0188","LU1688375341.USD","LU2097828557.USD","LU1820825898.SGD","LU2580892789.USD","SGXZ49509284.SGD","002142","LU2097828714.EUR","LU1146622755.USD","BK0197","LU2097828631.EUR","BK0187","LU2097828805.USD","BK0201","LU0140636845.USD","BK0028","02591","BK0278","BK1161","KTH","LU2328871848.SGD","LU2097828474.EUR"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":61,"code":"91000000","status":"200"}]}}